Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 795 of 5804
-
New combo therapy aims to keep prostate cancer from coming back after surgery
Disease control OngoingThis phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent). Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of pros…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Double-Drug attack on advanced prostate cancer put to the test
Disease control OngoingThe purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than eit…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New heart valve implant offers hope for patients too sick for surgery
Disease control OngoingProspective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Blood test could predict cancer return after surgery
Knowledge-focused OngoingThe overall objective of these studies are to confirm that ctDNA detected in plasma after intended curative treatment for CRC can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New psoriasis drug bimekizumab outperforms secukinumab in major trial
Disease control CompletedThis is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Triple-Drug cocktail targets tough lung cancer mutations
Disease control OngoingThe purpose of this study is to test the safety of combining Osimertinib with either Cisplatin or Carboplatin (at different dose levels) and Etoposide, to find out what effects, if any, this combination of drugs has on people with EGFR mutant lung cancer.
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could earlier testing for pregnancy diabetes prevent complications?
Disease control TerminatedContext: Women with gestational diabetes have excessive fetus growth weeks earlier than the screening period recommended currently, suggesting that earlier screening and intervention may improve pregnancy outcomes and the health of the offspring. Objective: To determine if early…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Scarless procedure may keep precancerous esophagus changes from returning
Disease control ENROLLING_BY_INVITATIONBarrett's esophagus (BE) is a precancerous lesion characterized by the replacement of the normal stratified squamous epithelium of the distal esophagus by intestinal metaplasia (IM). Non-dysplastic BE may progress to low-grade dysplasia (LGD), to high-grade dysplasia (HGD) and es…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in Gene-Matched tumors
Disease control OngoingThis phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafi…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy offers hope for melanoma patients who failed standard treatment
Disease control OngoingThis phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could antibody infusions replace daily HIV pills?
Disease control CompletedThe proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination…
Phase: PHASE1 • Sponsor: Rockefeller University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Poop pills? fecal transplants show promise for gut infections
Disease control CompletedThe study will provide data to show the effectiveness of Fecal Microbiota Transplant in patients with recurrent Clostridium difficile infection. Fecal Microbiota Transplant (FMT) is a procedure in which healthy colon contents of a carefully screened donor is inserted into the co…
Phase: PHASE4 • Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene Therapy's lasting effects on vision tracked in Long-Term study
Disease control CompletedThe objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be com…
Phase: PHASE3 • Sponsor: NightstaRx Ltd, a Biogen Company • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Implanted electrical system aims to restore movement in paralyzed limbs
Disease control Recruiting nowThe purpose of this study is to evaluate a surgically implanted functional electrical stimulation (FES) system to facilitate exercise, standing, stepping and/or balance in people with various degrees of paralysis.
Phase: NA • Sponsor: Case Western Reserve University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Mind over muscles: brain chip lets paralyzed man grasp objects
Disease control CompletedThis study is for people who have a paralyzed arm and hand from a spinal cord injury, who have also received a recording electrode array in the brain as part of the BrainGate study. The study will look at the ability of these participants to control different grasping patterns of…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Heart attack prevention: does opening a blocked artery save lives?
Disease control OngoingRandomized registry for the study of CTO PCI as adjunction to optimal medical therapy.
Phase: NA • Sponsor: Leif Thuesen • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedImmune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with vascular invasions
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a triple therapy beat back tough liver cancer?
Disease control CompletedAnti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors (VEGF/TKI-ICI) plus Immune checkpoint inhibitors (ICIs) are recommended for patients with unresectable hepatocellular carcinoma (HCC) with PVTT in China. However, these treatments have limited survival be…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo approach before surgery may improve outcomes for massive liver tumors
Disease control CompletedThis retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system. Patients were divided into a neoadjuvant conversion-first cohort and an upfront surger…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New combo therapy offers hope for older leukemia patients
Disease control CompletedThe trial proposed here attempts to reduce induction chemotherapy to phase I of standard induction in patients with B-precursor ALL. Induction phase II will be replaced by blinatumomab. The initial treatment phase is followed by sequential chemotherapy and further blinatumomab c…
Phase: PHASE2 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC